Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Colon cancer is the disease characterized by the development of malignant cells in the lining or epithelium of the first and longest portion of the large intestine.
Multimodal NPs for cancer theranostics show selective release, uptake, and reduced cancer cell survival when combined with radiation. In vivo tracking confirms efficacy with minimal side effects by targeted NPs containing chemo/radio/contrast agents.
Eukaryotic initiation translation factor 3 subunit h (EIF3H) possesses an alternative “moonlighting” function of deubiquitinase, while its role in colorectal carcinogenesis remains to be explored. Here the authors show that EIF3H deubiquitinates and stabilizes HAX1, which enhances RAF-MEK-ERK signaling to promote colorectal tumor growth and metastasis.
In a recent study published in Nature, Goto et al. explore mechanisms of immune evasion in early colorectal cancers and adenomas and identify SOX17 to be crucial for immune escape through suppression of interferon-γ signalling.
Self-renewing cancer stem cells drive tumor initiation and progression and represent a major target for therapeutic development. A study now shows that vanoxerine, a dopamine transporter antagonist, precisely inhibits this cell population in colorectal cancer, which leads to attenuation of tumor initiation and increased infiltration by immune cells.
We characterized cancer cells, immune responses and the microbiota composition in a cohort of primary colon cancers. Multi-omic analyses defined parameters associated with favorable prognosis, including a score that captured the intratumoral immune response and a specific microbiome signature. This data repository (atlas and compass of immune–cancer–microbiome interactions (AC-ICAM)) is publicly available.
Colon capsule endoscopy (CCE) is used for restricted indications only. Growing demand for out-of-hospital treatment combined with technical and clinical improvements in quality has made a wider use plausible. Artificial intelligence-supported footage analysis and quality assessment might further improve quality and reduce the price of CCE to a competitive level.